TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with immune checkpoint inhibitors in unresectable hepatocellular carcinoma (HCC) patients.

Trial Details

NCT ID
NCT04988945
Phase
PHASE2
Sponsor
The University of Hong Kong
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • TACE
  • SBRT
  • Durvalumab
  • Tremelimumab
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • For inclusion in the study, patients should fulfill the following criteria:
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF…
  • Diagnosis of unresectable HCC confirmed pathologically or made according to
  • American Association for the Study of Liver Diseases (AASLD) practice guideline 2010:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →